Inflammation Investigated as a Source of Pharmacokinetic Variability of Atazanavir in AIDS Clinical Trials Group Protocol A5224s

Erlandson K.M. , O'Riordan M. , Labbato D. , McComsey G.A. Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy. J Acquir Immune Defic Syndr 2014; 65: 290–298.

McComsey G.A. , Kitch D. , Sax P.E. Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Acquir Immune Defic Syndr 2014; 65: 167–174.

Rönsholt F.F. , Ullum H. , Katzenstein T.L. , Gerstoft J. , Ostrowski S.R. Persistent inflammation and endothelial activation in HIV-1 infected patients after 12 years of antiretroviral therapy. PLoS One 2013; 8: e65182.

Wada N.I. , Jacobson L.P. , Margolick J.B. The effect of HAART-induced suppression on circulating markers of inflammation and immune activation. AIDS 2015; 29: 463–471.

Tilton J.C. , Johnson A.J. , Luskin M.R. Diminished production of monocyte proinflammatory cytokines during human immunodeficiency virus viremia is mediated by type I interferons. J Virol 2006; 80: 11486–11497.

Sereti I. , Krebs S. , Phanuphak N. Initiation of antiretroviral therapy in early HIV infection reduces but does not abrogate chronic residual inflammation. Clin Infect Dis 2017; 64: 124–131.

Morgan E.T. , Goralski K.B. , Piquette-Miller M. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 2008; 36: 205–216.

Seifert S.M. , Castillo-Mancilla J.R. , Erlandson K.M. , Anderson P.L. Inflammation and pharmacokinetics: potential implications for HIV-infection. Expert Opin Drug Metab Toxicol 2017; 13: 641–650.

Aitken A.E. , Morgan E.T. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6, and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 2007; 35: 1687–1693.

Cressman A.M. , Petrovic V. , Piquette-Miller M. Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response. Expert Rev Clin Pharmacol 2012; 5: 69–89.

Schmith V.D. , Foss J.F. Inflammation: planning for a source of pharmacokinetic/pharmacodynamic variability in translational studies. Clin Pharmacol Ther 2010; 87: 488–491.

Slaviero K.A. , Clark S.J. , Rivory L.P. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003; 4: 224–232.

Frye R.F. , Schneider V.M. , Frye C.S. , Feldman A.M.J. Plasma levels of TNF-α and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail 2002; 8: 315–319.

Chen Y.L. , Le Vraux V. , Leneveu A. Acute phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther 1994; 55: 649–660.

Encalada Ventura M.A. , van Wanrooy M.J. , Span L.F. Longitudinal analysis of the effect of inflammation on voriconazole trough concentrations. Antimicrob Agents Chemother 2016; 60: 2727–2731.

Jones A.E. , Brown K.C. , Werner R.E. Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol 2010; 66: 475–485.

Connolly N.C. , Riddler S.A. , Rinaldo C.R. Proinflammatory cytokines in HIV disease – A review and rationale for new therapeutic approaches. AIDS Rev 2005; 7: 168–180.

Kis O. , Sankaran-Walters S. , Tozammel Hoque M. , Walmsley S.L. , Dandekar S. , Bendayan R. HIV-1 alters intestinal expression of drug transporters and metabolic enzymes: implications for antiretroviral drug disposition. Antimicrob Agents Chemother 2016; 60: 2771–2781.

Bentué-Ferrer D. , Arvieux C. , Tribut O. , Ruffault A. , Bellissant E. Clinical pharmacology, efficacy and safety of atazanavir: a review. Expert Opin Drug Metab Toxicol 2009; 5: 1455–1468.

Keshavan P. , Deem T.L. , Schwemberger S.L. , Babcock G.F. , Cook-Mills J.M. , Zucker S.D. Unconjugated bilirubin inhibits VCAM-1-mediated transendothelial leukocyte migration. J Immunol 2005; 174: 3709–3718.

Stocker R. , Yamamoto Y. , McDonagh A.F. , Glazer A.N. , Ames B.N. Bilirubin is an antioxidant of possible physiological importance. Science 1987; 235: 1043–1046.

Stocker R. , Glazer A.N. , Ames B.N. Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci U S A 1987; 84: 5918–5922.

Sax P.E. , Tierney C. , Collier A.C. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361: 2230–2240.

Daar E.S. , Tierney C. , Fischl M.A. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154: 445–456.

Sax P.E. , Tierney C. , Collier A.C. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011; 204: 1191–1201.

McComsey G.A. , Kitch D. , Sax P.E. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis 2011; 53: 185–196.

McComsey G.A. , Kitch D. , Daar E.S. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ ritonavir. AIDS 2012; 26: 1371–1385.

Venuto C.S. , Mollan K. , Ma Q. Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202. J Antimicrob Chemother 2014; 69: 3300–3310.

Keil K. , Hochreitter J. , DiFrancesco R. Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application. Ther Drug Monit 2007; 29: 103–109.

Bland J.M. , Altman D.G. Statistics notes: calculating correlation coefficients with repeated observations: part 1 – correlation within subjects. BMJ 1995; 310: 446.

Aitken A.E. , Richardson T.A. , Morgan E.T. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 2006; 46: 123–149.

Deeks S.G. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62: 141–155.

Hunt P.W. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 2012; 9: 139–147.

Kalayjian R.C. , Machekano R.N. , Rizk N. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis 2010; 201: 1796–1805.

Neuhaus J. , Jacobs D.R. Jr. , Baker J.V. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201: 1788–1795.

De Pablo-Bernal R.S. , Ruiz-Mateos E. , Rosado I. TNF-alpha levels in HIV-infected patients after long-term suppressive cART persist as high as in elderly, HIV-uninfected subjects. J Antimicrob Chemother 2014; 69: 3041–3046.

Triant V.A. , Meigs J.B. , Grinspoon K. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51: 268–273.

Ross A.C. , Rizk N. , O'Riordan M.A. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009; 49: 1119–1127.

Nadin L. , Butler A.M. , Farrell G.C. , Murray M. Pretranslational down-regulation of cytochromes P450 2C11 and 3A2 in male rat liver by tumor necrosis factor a. Gastroenterology 1995; 109: 198–205.

Morgan E.T. , Thomas K.B. , Swanson R. , Vales T. , Hwang J. , Wright K. Selective suppression of cytochrome P450 gene expression by interleukins 1 and 6 in rat liver. Biochim Biophys Acta 1994; 1219: 475–483.

Barclay T.B. , Peters J.M. , Sewer M.B. , Ferrari L. , Gonzalez F.J. , Morgan E.T. Modulation of cytochrome P-450 gene expression in endotoxemic mice is tissue specific and peroxisome proliferator-activated receptor-alpha dependent. J Pharmacol Exp Ther 1999; 290: 1250–1257.

Fang C. , Yoon S.J. , Tindberg N. , Jarvelainen H.A. , Lindros K.O. , Ingelman-Sundberg M. Hepatic expression of multiple acute proteins and down-regulation of nuclear receptors after acute endotoxin exposure. Biochem Pharmacol 2004; 67: 1389–1397.

Morgan E.T. Regulation of cytochrome P450 by inflammatory mediators: why and how? Drug Metab Dispos 2001; 29: 207–212.

Mazzone G.L. , Rigato I. , Ostrow J.D. Bilirubin inhibits the TNF alpha-related induction of three endothelial adhesion molecules. Biochem Biophys Res Commun 2009; 386: 338–344.

Vogel M.E. , Zucker S.D. Bilirubin acts as an endogenous regulator of inflammation by disrupting adhesion molecule-mediated leukocyte migration. Inflamm Cell Signal 2016; 3: e1178.

Kelesidis T. , Tran T.T.T. , Stein J.H. Changes in inflammation and immune activation with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy: ACTG 5260s. Clin Infect Dis 2015; 61: 651–660.

Vogel M.E. , Idelman G. , Konaniah E.S. , Zucker S.D. Bilirubin prevents atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice by inhibiting endothelial VCAM-1 and ICAM-1 signaling. J Am Heart Assoc 2017; 6: e004820.

Marconi V.C. , So-Armah K. , Tate J. Hyperbilirubinemia prevents cardiovascular disease for HIV+ and HIV-individuals. Conference on Retroviruses and Opportunistic Infections. 13–16 February 2017, Seattle, WA, USA. Abstract 127.

Rosenblatt L. , Farr A.M. , Nkhoma E.T. , Nelson J.K. , Ritchings C. , Johnston S.S. Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort-study. BMC Infect Dis 2016; 16: 492.

Chow D. , Shikuma C. , Ritchings C. , Guo M. , Rosenblatt L. Atazanavir and cardiovascular risk among human immunodeficiency virus-infected patients: a systematic review. Infect Dis Ther 2016; 5: 473–489.